Article Dans Une Revue Blood Année : 2024

RAS/RAF landscape in monoclonal plasma cell conditions

Adam Sciambi
  • Fonction : Auteur

Résumé

Multiple myeloma is characterized by a huge heterogeneity at the molecular level. The RAS/RAF pathway is the most frequently mutated, in ∼50% of the patients. However, these mutations are frequently subclonal, suggesting a secondary event. Because these genes are part of our routine next-generation sequencing panel, we analyzed >10 000 patients with different plasma cell disorders to describe the RAS/RAF landscape. In this large cohort of patients, almost 61% of the patients presented a RAS/RAF mutation at diagnosis or relapse, but much lower frequencies occurred in presymptomatic cases. Of note, the mutations were different from that observed in solid tumors (higher proportions of Q61 mutations). In 29 patients with 2 different mutations, we were able to perform single-cell sequencing, showing that in most cases, mutations occurred in different subclones, suggesting an ongoing mutational process. These findings suggest that the RAS/RAF pathway is not an attractive target, both on therapeutic and residual disease assessment points of view.

Dates et versions

hal-05026345 , version 1 (09-04-2025)

Identifiants

Citer

Anais Schavgoulidze, Jill Corre, Mehmet Kemal Samur, Celine Mazzotti, Luka Pavageau, et al.. RAS/RAF landscape in monoclonal plasma cell conditions. Blood, 2024, 144 (2), pp.201-205. ⟨10.1182/blood.2023022295⟩. ⟨hal-05026345⟩
40 Consultations
0 Téléchargements

Altmetric

Partager

  • More